Drug Type Synthetic peptide |
Synonyms Antiplatelet thrombolysin, Declotana, ZK 001 + [1] |
Target |
Mechanism GP1BA inhibitors(glycoprotein Ib platelet subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | CN | 01 Jul 2019 | |
ST Elevation Myocardial Infarction | Phase 2 | CN | 01 Aug 2015 | |
Non-St Elevated Myocardial Infarction | Phase 2 | CN | 01 Jul 2012 | |
Acute Coronary Syndrome | Phase 1 | CN | 14 Jan 2016 | |
Thrombosis | Phase 1 | CN | 15 Nov 2013 | |
Thrombosis | Phase 1 | CA | 15 Nov 2013 | |
Thrombosis | Phase 1 | HK | 15 Nov 2013 | |
Blood Coagulation Disorders | Phase 1 | - | 01 Sep 2010 | |
Coronary Disease | Phase 1 | - | 01 Sep 2010 | |
Acute Ischemic Stroke | IND Approval | CN | 05 Dec 2024 |